Jing Zhao

Mar 3, 2025 | nature.com | Yiyong Xian |Fang Liu |Zhe Zhang |Lingling Niu |Wanru Shi |Xiaoying Wang | +3 more

To compare the long-term outcomes of monovision surgery using implantable collamer lens (ICL) V4c and femtosecond laser-assisted in situ keratomileusis (FS-LASIK) in myopic patients with early presbyopia. This case series study included 48 eyes of 24 patients (male/female: 10/14, mean age 45.50 ± 3.82 years) and followed-up for 4.5 years (54.00 ± 9.77 months). Patients were examined for spherical equivalent, uncorrected distance visual acuity, corrected distance visual acuity, intraocular pressure, presbyopic add power, visual acuity (VA) (logMAR) of dominant eyes (D-eye), non-dominant eyes (nD-eye), and both eyes (Bi) at 0.4 m, 0.8 m, and 5 m, corneal wavefront aberration, and contrast sensitivity (CS). All surgeries were uneventful. The safety indices of ICL V4c group and FS-LASIK group were 1.17 ± 0.30 and 0.98 ± 0.20 (p < 0.05), and the efficacy indices were 0.79 ± 0.07 and 0.52 ± 0.07 (p < 0.05) respectively. The binocular VA (logMAR) of ICL V4c group and FS-LASIK group at 5.0 m were: 0.02 ± 0.11, 0.18 ± 0.30; 0.8 m: 0.09 ± 0.12, − 0.01 ± 0.11; 0.4 m: − 0.02 ± 0.06, − 0.03 ± 0.08, (p > 0.05 at three distances). Compared with ICL V4c group, lower CS was observed at 1.0 cpd in the FS-LASIK group (1.07 ± 0.31 vs. 0.80 ± 0.51, p = 0.043). Monovision surgery using ICL V4c and FS-LASIK provides good binocular visual acuity at near-to-far distances in myopia patients in the presbyopia age group.

Nov 27, 2023 | nature.com | Li Zhang |Xudong WANG |Jing Zhao |Lin Tian |Shaolong Zhang |Anhua Lei | +17 more

Chimeric antigen receptor (CAR) T cell therapies have successfully treated hematological malignancies. Macrophages have also gained attention as an immunotherapy owing to their immunomodulatory capacity and ability to infiltrate solid tumors and phagocytize tumor cells. The first-generation CD3ζ-based CAR-macrophages could phagocytose tumor cells in an antigen-dependent manner. Here we engineered induced pluripotent stem cell-derived macrophages (iMACs) with toll-like receptor 4 intracellular toll/IL-1R (TIR) domain-containing CARs resulting in a markedly enhanced antitumor effect over first-generation CAR-macrophages. Moreover, the design of a tandem CD3ζ-TIR dual signaling CAR endows iMACs with both target engulfment capacity and antigen-dependent M1 polarization and M2 resistance in a nuclear factor kappa B (NF-κB)-dependent manner, as well as the capacity to modulate the tumor microenvironment. We also outline a mechanism of tumor cell elimination by CAR-induced efferocytosis against tumor cell apoptotic bodies. Taken together, we provide a second-generation CAR-iMAC with an ability for orthogonal phagocytosis and polarization and superior antitumor functions in treating solid tumors relative to first-generation CAR-macrophages. Induced pluripotent stem cell (iPSC)-derived macrophages (iMACs) are being used to make chimeric antigen receptor (CAR) macrophages for immunotherapy. Here the authors design a second-generation macrophage-specific CAR by integrating CD3ζ and toll/IL-1R (TIR) domains resulting in an M1-polarized CAR-iMAC with increased antitumor functions.